Mayo Clinic researchers examined data on more than 16,000 hospitalized patients in the U.S., and found that those who received the sleeping pill Ambien, or zolpidem, fell at a rate four times greater than those who didn't receive the treatment. Due to the research, Mayo is transitioning to other sleep-enhancement treatments, said Dr. Timothy Morgenthaler, Mayo's chief patient safety officer.
Sleep drug may increase risk of falls, study finds
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||